Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 2Urinary Bladder Neoplasms 1Testicular Neoplasms 1Sarcoma 1Prostatic Neoplasms 1

Interventions

pembrolizumab 12Nivolumab 10cemiplimab 5avelumab 5Ipilimumab 5atezolizumab 4poly ICLC 3fludarabine 3durvalumab 3Gemcitabine 3Cyclophosphamide 3Biopsy 3utomilumab 2ulixertinib 2pertuzumab 2osimertinib 2aldesleukin 2Trastuzumab 2Standard of Care 2Sirolimus 2Radiosurgery 2Psychiatric Rehabilitation 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Immunoglobulin G 2Docetaxel 2Disulfides 2Blood Specimen Collection 2zimberelimab 1vocimagene amiretrorepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Histocompatibility Testing × Dermatologic × Clear all
NCT05819827 2025-04-27

Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics

Mayo Clinic

Terminated
13 enrolled
DermatologicGenitourinarySarcoma

Urinary Bladder Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡